Repare Therapeutics Inc. (RPTX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
RPTX Chart
Repare Therapeutics Inc. (RPTX) Reports Break-Even Earnings for Q3
Repare Therapeutics Inc. (RPTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.81 per share a year ago.
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.82 per share a year ago.
What Makes Repare Therapeutics (RPTX) a New Buy Stock
Repare Therapeutics (RPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Repare Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 2,025 | $43 | $43 | - | - |
Repare Therapeutics Inc. (RPTX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Repare Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Steve Forte CEO | NASDAQ (NGS) Exchange | 760273102 CUSIP |
| CA Country | 129 Employees | - Last Dividend | - Last Split | 19 Jun 2020 IPO Date |
Overview
Repare Therapeutics Inc. is a pioneering force in the realm of precision oncology, operating principally in Canada and the United States. The company stands out thanks to its innovative synthetic lethality approach towards the development of cancer therapeutics. Synthetic lethality occurs when the combination of mutations in two or more genes leads to cell death, whereas a mutation in just one gene does not, and Repare Therapeutics leverages this principle to target and kill cancer cells while sparing healthy ones. Their cutting-edge SNIPRx platform, which is both proprietary and CRISPR-enabled, spans genome-wide operations to discover, validate, and cultivate a robust pipeline of SL-based therapeutics. These focus particularly on genomic instability issues, such as DNA damage repair. Since its inception in 2016, Repare Therapeutics has cemented its presence in the industry, partnering with several prestigious organizations and continuously advancing in its mission from its headquarters in Montréal, Canada.
Products and Services
Camonsertib (RP-3500): Serving as the lead product candidate, Camonsertib is an oral small molecule inhibitor currently undergoing Phase ½ development. Its therapeutic focus lies in treating solid tumors that exhibit specific DNA damage repair-related genomic alterations. This product exemplifies Repare Therapeutics’ commitment to harnessing synthetic lethality for oncological precision medicine.
Lunresertib (RP-6306): This promising product is a PKMYT1 Inhibitor under Phase 1 clinical trial. Its target demographic includes patients with tumors characterized by genetic alterations manifested through CCNE1 amplification. Lunresertib represents an innovative approach to targeting cancer’s genetic vulnerabilities.
RP-1664: Another critical element of Repare Therapeutics' pipeline, RP-1664, is an oral PLK4 inhibitor. Also in Phase 1 clinical trial, this product is designed to exploit the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors. It's a strategic advancement in the understanding and treatment of cancer at the genetic level.
RP-3467: An inhibitor of the polymerase theta adenosinetriphosphatase (ATPase), RP-3467 is currently under development as a SL target associated with BRCA mutations and other genomic alterations. This product candidate showcases Repare Therapeutics' focus on using synthetic lethality to address specific genetic configurations that promote cancer proliferation.
Aside from its innovative pipeline, Repare Therapeutics has established significant license and collaboration agreements. These partnerships include agreements with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co. Additionally, a clinical study and collaboration agreement with Debiopharm aims to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer, emphasizing the collaborative and forward-thinking approach of Repare Therapeutics Inc. in the fight against cancer.
